Tripping into the unknown: Exploring the experiences of first-time LSD users through global drug survey insights.

Drugs LSD harm reduction peers psychedelic

Journal

Journal of psychopharmacology (Oxford, England)
ISSN: 1461-7285
Titre abrégé: J Psychopharmacol
Pays: United States
ID NLM: 8907828

Informations de publication

Date de publication:
28 May 2024
Historique:
medline: 28 5 2024
pubmed: 28 5 2024
entrez: 28 5 2024
Statut: aheadofprint

Résumé

The recreational use of LSD, a synthetic psychedelic drug, has surged in recent years, coinciding with a renewed research focus on its potential psychotherapeutic properties. This study aims to describe the experiences and perceptions of individuals engaging in LSD use for the first time, derived from a large international sample. This study utilised 2018 Global Drug Survey data collected from 6 November 2017 to 10 January 2018. Participants who initiated LSD use in the preceding 12 months answered questions on their experiences, social settings, harm-reduction behaviours, and demographics. Descriptive statistics were employed, and characteristics of those seeking emergency medical treatment (EMT) and those not planning further LSD use were compared with other respondents. Among 3340 respondents who used LSD in the past year, their first-time experiences generally exceeded expectations, with 97.7% expressing excitement. Adverse and unwanted side effects were rarely reported, and only 17 individuals needed EMT. Feelings of fear were reported by most (64.1%), but only very mildly and not enough to put them off from wanting to use LSD again. Although the occurrence of unwanted side effects seems low and the LSD experience is generally pleasurable, vigilance amid the rising illicit use of LSD through harm-reduction education is still important in preventing possible risks.

Sections du résumé

BACKGROUND UNASSIGNED
The recreational use of LSD, a synthetic psychedelic drug, has surged in recent years, coinciding with a renewed research focus on its potential psychotherapeutic properties.
AIM UNASSIGNED
This study aims to describe the experiences and perceptions of individuals engaging in LSD use for the first time, derived from a large international sample.
METHODS UNASSIGNED
This study utilised 2018 Global Drug Survey data collected from 6 November 2017 to 10 January 2018. Participants who initiated LSD use in the preceding 12 months answered questions on their experiences, social settings, harm-reduction behaviours, and demographics. Descriptive statistics were employed, and characteristics of those seeking emergency medical treatment (EMT) and those not planning further LSD use were compared with other respondents.
RESULTS UNASSIGNED
Among 3340 respondents who used LSD in the past year, their first-time experiences generally exceeded expectations, with 97.7% expressing excitement. Adverse and unwanted side effects were rarely reported, and only 17 individuals needed EMT. Feelings of fear were reported by most (64.1%), but only very mildly and not enough to put them off from wanting to use LSD again.
DISCUSSION UNASSIGNED
Although the occurrence of unwanted side effects seems low and the LSD experience is generally pleasurable, vigilance amid the rising illicit use of LSD through harm-reduction education is still important in preventing possible risks.

Identifiants

pubmed: 38804544
doi: 10.1177/02698811241254837
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

2698811241254837

Déclaration de conflit d'intérêts

Declaration of conflicting interestsThe author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Auteurs

Luke Baxter (L)

South London and Maudsley NHS Trust/King's College London, London, UK.

Cheneal Puljević (C)

School of Public Health, The University of Queensland, Brisbane, QLD, Australia.

Tim Piatkowski (T)

School of Applied Psychology, Griffith Centre for Mental Health, Griffith University, Mount Gravatt, QLD, Australia.

Jason Ferris (J)

Centre for Health Services Research, The University of Queensland, Brisbane, QLD, Australia.

Emma L Davies (EL)

Centre for Psychological Research, Oxford Brookes University, Oxford, UK.

Monica J Barratt (MJ)

Social Equity Research Centre and Digital Ethnography Research Centre, RMIT University, Melbourne, VIC, Australia.
National Drug and Alcohol Research Centre, UNSW Sydney, Sydney, NSW, Australia.

Adam Winstock (A)

Global Drug Survey, London, UK.
Institute of Epidemiology, University College London, London, UK.

Classifications MeSH